ArticleAdvanced healthcare materials2023
Nanovaccines Displaying the Influenza Virus Hemagglutinin in an Inverted Orientation Elicit an Enhanced Stalk-Directed Antibody Response.
Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Structural vaccinology expedites rational design of next-generation vaccines for influenza and respiratory syncytial virus.Virologica Sinica · 2026Review
- Hemagglutinin-displaying influenza nanovaccines: progress and promise.Nanomedicine (London, England) · 2026Review
- Characterization and immunogenicity of nanoparticle vaccines based on Clade 2 and Clade 3 sarbecovirus S2 proteins.NPJ vaccines · 2025Article
- Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses.NPJ vaccines · 2025Article
- Research Progress of Universal Influenza Vaccine.Vaccines · 2025Review
- Merbecovirus S2 subunit vaccines elicit cross reactive antibodies and provide partial protection against MERS coronavirus.Npj viruses · 2025Article
- Multilayer Adjuvanted Influenza Protein Nanoparticles Improve Intranasal Delivery and Antigen-Specific Immunity.ACS nano · 2025Article
- Tethered Antigenic Suppression Shields the Hemagglutinin Head Domain and Refocuses the Antibody Response to the Stalk Domain.Chemistry (Basel, Switzerland) · 2025Article
- Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice.Nature communications · 2025Article
- MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review.Frontiers in immunology · 2025Review
- Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing.ACS central science · 2024Article
- Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity.Bioengineering & translational medicine · 2024Article
- Vaccine design via antigen reorientation.Nature chemical biology · 2024Article
- Engineering a SARS-CoV-2 vaccine targeting the RBD cryptic-face via immunofocusing.bioRxiv : the preprint server for biology · 2024Article
- Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge.NPJ vaccines · 2024Article
- Bringing immunofocusing into focus.NPJ vaccines · 2024Review
- Antigen spacing on protein nanoparticles influences antibody responses to vaccination.Cell reports · 2023Article
- A novel "prime and pull" strategy mediated by the combination of two dendritic cell-targeting designs induced protective lung tissue-resident memory T cells against H1N1 influenza virus challenge.Journal of nanobiotechnology · 2023Article
- Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles.Biopolymers · 2023Review
- Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the availability of licensed vaccines, influenza causes considerable morbidity and mortality worldwide. Current influenza vaccines elicit an immune response that primarily targets the head domain of the viral glycoprotein hemagglutinin (HA). Influenza viruses, however, readily evade this response by acquiring mutations in the head domain. While vaccines that target the more conserved HA stalk may circumvent this problem, low levels of antistalk antibodies are elicited by vaccination, possibly due to the poor accessibility of the stalk domain to B cell receptors. In this work, it is demonstrated that nanoparticles presenting HA in an inverted orientation generate tenfold higher antistalk antibody titers after a prime immunization and fivefold higher antistalk titers after a boost than nanoparticles displaying HA in its regular orientation. Moreover, nanoparticles presenting HA in an inverted orientation elicit a broader antistalk response that reduces mouse weight loss and improves survival after challenge to a greater extent than nanoparticles displaying HA in a regular orientation. Refocusing the antibody response toward conserved epitopes by controlling antigen orientation may enable the design of broadly protective nanovaccines targeting influenza viruses and other pathogens with pandemic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.